“Built‐in” PD‐1 blocker to rescue NK‐92 activity from PD‐L1–mediated tumor escape mechanisms

Success of adoptive cell therapy mainly depends on the ability of immune cells to persist and function optimally in the immunosuppressive tumor microenvironment. Although present at the cancer site, immune cells become exhausted and/or inhibited, due to the presence of inhibitory receptors such as PD‐L1 on malignant cells. Novel genetic strategies to manipulate the PD1/PD‐L1 axis comprise (i) PD‐1 reversion where the receptor intracellular...